α-CGRP (mouse, rat) TFA can regulate the innate lymphoid cell response in 2 groups[1].
α-CGRP (mouse, rat) TFA regulates insulin secretion and reduces the risk of type 2 diabetes[2].
α-CGRP (mouse, rat) TFA (0.25, 0.5, 1 μg/kg/min, intravenous) dose-dependent decreases mean arterial blood pressure, while heart rate and systemic vascular conduction increased, while cardiac output remained unchanged[3].
α-CGRP (mouse, rat) TFA plays an important role in the regulation of Kainic acid (KA) induced pyramid-cell death in hippocampal CA3 region[4].
References:
[1]. Whitby K, et al. Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J Virol. 2005 Jul;79(14):8698-706.
[2]. Xu H, et al. Transcriptional Atlas of Intestinal Immune Cells Reveals that Neuropeptide α-CGRP Modulates Group 2 Innate Lymphoid Cell Responses. Immunity. 2019 Oct 15;51(4):696-708.e9.
[3]. Arulmani U, et al. Effects of the calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS on alpha-CGRP-induced regional haemodynamic changes in anaesthetised rats. Basic Clin Pharmacol Toxicol. 2004 Jun;94(6):291-7.
[4]. Park SH, et al. Role of α-CGRP in the regulation of neurotoxic responses induced by kainic acid in mice. Peptides. 2013 Jun;44:158-62.
















